X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cabotegravir (61) 61
index medicus (42) 42
pharmacology & pharmacy (27) 27
rilpivirine (27) 27
pharmacokinetics (24) 24
humans (23) 23
dolutegravir (20) 20
infectious diseases (18) 18
hiv (17) 17
hiv infections - drug therapy (17) 17
immunology (17) 17
bictegravir (16) 16
gsk1265744 (16) 16
safety (14) 14
infection (13) 13
aids/hiv (12) 12
animals (12) 12
microbiology (12) 12
anti-hiv agents - administration & dosage (11) 11
antiretroviral therapy (11) 11
antiviral agents (10) 10
hiv-1 (10) 10
anti-hiv agents - pharmacology (9) 9
preexposure prophylaxis (9) 9
prevention (9) 9
pyridones - administration & dosage (9) 9
resistance (9) 9
virology (9) 9
pre-exposure prophylaxis (8) 8
pyridones - pharmacology (8) 8
raltegravir (8) 8
adult (7) 7
adults (7) 7
hiv-1 - drug effects (7) 7
integrase (7) 7
long-acting (7) 7
strand transfer inhibitor (7) 7
therapy (7) 7
drug delivery systems (6) 6
drug therapy (6) 6
female (6) 6
formulation (6) 6
hiv infection (6) 6
integrase inhibitors (6) 6
male (6) 6
pharmacology (6) 6
young adult (6) 6
antiviral activity (5) 5
double-blind (5) 5
drug resistance (5) 5
elvitegravir (5) 5
health aspects (5) 5
hiv infections - prevention & control (5) 5
hiv infections - virology (5) 5
hiv integrase inhibitors - pharmacology (5) 5
hiv-1 infection (5) 5
hiv-1 integrase (5) 5
human immunodeficiency virus--hiv (5) 5
human-immunodeficiency-virus (5) 5
integrase inhibitor (5) 5
phase 2b (5) 5
reverse-transcriptase inhibitors (5) 5
rilpivirine - administration & dosage (5) 5
tenofovir (5) 5
anti-retroviral agents - administration & dosage (4) 4
anti-retroviral agents - pharmacokinetics (4) 4
antiretroviral drugs (4) 4
article (4) 4
delayed-action preparations - administration & dosage (4) 4
dosage and administration (4) 4
drug interactions (4) 4
drug-resistance (4) 4
drugs (4) 4
highly active antiretroviral therapy (4) 4
inhibitor (4) 4
inhibitors (4) 4
long-acting injectable (4) 4
macaca mulatta (4) 4
middle aged (4) 4
mk-8591 (4) 4
protects macaques (4) 4
pyridones - pharmacokinetics (4) 4
release (4) 4
tenofovir alafenamide (4) 4
tissue (4) 4
tolerability (4) 4
transmission (4) 4
acquired immune deficiency syndrome--aids (3) 3
adolescent (3) 3
african women (3) 3
anti-hiv agents - chemistry (3) 3
anti-hiv agents - pharmacokinetics (3) 3
antiretroviral (3) 3
antiretroviral therapy, highly active - methods (3) 3
antiretroviral-naive adults (3) 3
articles (3) 3
chemistry, multidisciplinary (3) 3
clinical trials (3) 3
clinical trials, phase ii as topic (3) 3
cross-over studies (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Infectious Diseases, ISSN 0022-1899, 2018, Volume 218, Issue 11, pp. 1773 - 1776
Bictegravir (BIC) and cabotegravir (CAB) are the latest available HIV integrase inhibitors in clinical trials. The combination of major integrase inhibitor... 
Integrase resistance testing | Phenotype | Integrase inhibitors | Bictegravir, cabotegravir | Dolutegravir | phenotype | integrase inhibitors | bictegravir | INFECTIOUS DISEASES | RALTEGRAVIR | integrase resistance testing | MICROBIOLOGY | dolutegravir | IMMUNOLOGY | cabotegravir
Journal Article
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, ISSN 0066-4804, 01/2020, Volume 64, Issue 1
Second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) dolutegravir (DTG), bictegravir (BIC), and cabotegravir (CAB) showed a high genetic... 
integrase inhibitors | bictegravir | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | dolutegravir | phenotypic assay | cabotegravir | HIV-1 resistance
Journal Article
Organic Process Research and Development, ISSN 1083-6160, 2019, Volume 23, Issue 5, pp. 716 - 729
Bictegravir and dolutegravir are two recently approved integrase inhibitors for the treatment of HIV. A third inhibitor, cabotegravir, is in Phase 3... 
synthetic routes | bictegravir | integrase inhibitors | patents | dolutegravir | cabotegravir | CHEMISTRY, ORGANIC | CHEMISTRY, APPLIED
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 12/2019, Volume 82 Suppl 3, pp. S286 - S288
BACKGROUND:The key to maximizing the value of implementation science data is to get the learnings early. A critical contributor to early clinical research data... 
INFECTIOUS DISEASES | RILPIVIRINE | IMMUNOLOGY | business | CABOTEGRAVIR | implementation science | Researchers | Antiretroviral agents | Human immunodeficiency virus--HIV | Clinical trials | Research | Public health | Pharmaceuticals
Journal Article
CLINICAL INFECTIOUS DISEASES, ISSN 1058-4838, 08/2019, Volume 69, Issue 4, pp. 657 - 667
Background. Integrase strand transfer inhibitors (INSTIs) are crucial for the treatment of human immunodeficiency virus (HIV) type 2 infection, due to limited... 
bictegravir | INFECTIOUS DISEASES | DNA-BINDING | HIV-2 | integrase inhibitor | MICROBIOLOGY | DOLUTEGRAVIR | DRUG-RESISTANCE | IMMUNOLOGY | PHASE 2B | phenotypic resistance | REVERSE-TRANSCRIPTASE INHIBITORS | GENE | VITRO PHENOTYPIC SUSCEPTIBILITY | HIV-1 INTEGRASE | insertion | MUTATIONS | CABOTEGRAVIR
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 10/2019, Volume 311-312, pp. 201 - 211
Antiretroviral therapy requires lifelong daily dosing to attain viral suppression, restore immune function, and improve quality of life. As a treatment... 
Long-acting slow effective release antiretroviral therapy | Prodrugs | Monocyte-derived macrophages | Rilpivirine | Antiretroviral therapy | Nanoformulation | HIV-1 | SAFETY | TISSUE | RELEASE | FORMULATION | CHEMISTRY, MULTIDISCIPLINARY | ADHERENCE | RESERVOIRS | THERAPY | PHARMACOKINETICS | PHARMACOLOGY & PHARMACY | CABOTEGRAVIR
Journal Article
Antiviral Research, ISSN 0166-3542, 04/2018, Volume 152, pp. 1 - 9
Cabotegravir (CAB, S/GSK1265744) is an investigational second-generation integrase strand transfer inhibitor (INSTI) with a chemical structure similar to... 
Cabotegravir | Secondary mutations | HIV-1 integrase | Strand transfer inhibitor | SUBTYPE | RALTEGRAVIR | ADULTS | INTASOME | PHASE 2B | REVERSE-TRANSCRIPTASE INHIBITORS | VIROLOGY | IMMUNODEFICIENCY-VIRUS TYPE-1 | PHARMACOLOGY & PHARMACY | INFECTION | RILPIVIRINE | Index Medicus
Journal Article
European Journal of Pharmaceutics and Biopharmaceutics, ISSN 0939-6411, 05/2019, Volume 138, pp. 92 - 98
[Display omitted] Suboptimal adherence to antiretroviral (ARV) therapy can lead to insufficient drug exposure leading to viral rebound and increased likelihood... 
Long-Acting Injectable (LAI) | Maraviroc | Pre-exposure Prophylaxis (PrEP) | Nanodispersion | Intramuscular | Pharmacokinetics | Long-Acting Parenteral (LAP) | Nanomedicine | SAFETY | TISSUE | HIV PREEXPOSURE PROPHYLAXIS | FORMULATION | BIOAVAILABILITY | PHARMACOLOGY | PHARMACOLOGY & PHARMACY | INFECTION | ABSORPTION | CABOTEGRAVIR
Journal Article
International Journal of Mass Spectrometry, ISSN 1387-3806, 03/2019, Volume 437, pp. 92 - 98
[Display omitted] •Characterized injection depots of long-acting nanoformulation of cabotegravir.•Detected high levels of cabotegravir throughout depots at... 
Cabotegravir | Injection depot | Drug imaging | MALDI | Drug biodistribution | Imaging mass spectrometry | Drug development | SPECTROSCOPY | PHYSICS, ATOMIC, MOLECULAR & CHEMICAL | RELEASE | FORMULATION
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 04/2019, Volume 63, Issue 4
The potent antituberculosis activity and long half-life of bedaquiline make it an attractive candidate for use in long-acting/extended-release formulations for... 
BALB/c mice | Long-acting injectable | Latent tuberculosis infection | Bedaquiline | MYCOBACTERIUM-TUBERCULOSIS | TUBERCLE-BACILLI | MICROBIOLOGY | RIFAPENTINE | bedaquiline | REGIMENS | MURINE MODEL | long-acting injectable | STERILIZING ACTIVITY | PHARMACOLOGY | MULTIDRUG-RESISTANT TUBERCULOSIS | latent tuberculosis infection | PHARMACOLOGY & PHARMACY | RILPIVIRINE | CABOTEGRAVIR
Journal Article
Advanced Drug Delivery Reviews, ISSN 0169-409X, 06/2018, Volume 131, pp. 116 - 121
The use of solid drug nanoparticles (SDN) has become an established approach to improve drug delivery, supporting enhancement of oral absorption and... 
Design | Physiologicallybased Pharmacokinetic (PBPK) modelling | Pharmacokinetics | Solid drug nanoparticle | NANOSUSPENSIONS | PHARMACOLOGY & PHARMACY | RILPIVIRINE | OPPORTUNITIES | PARAMETERS | RELEASE | CABOTEGRAVIR | PREDICTION | Drugs | Drug delivery systems | Usage | Analysis | Vehicles
Journal Article
Drugs, ISSN 0012-6667, 2018, Volume 78, Issue 17, pp. 1817 - 1828
Bictegravir is a new integrase strand transfer inhibitor (INSTI) with a high genetic barrier to the development of HIV-1 resistance. The drug is co-formulated... 
TOLERABILITY | EMTRICITABINE | DOUBLE-BLIND | INITIAL TREATMENT | PHARMACOLOGY & PHARMACY | STRAND TRANSFER INHIBITOR | DOLUTEGRAVIR | TOXICOLOGY | PHASE-3 | BICTEGRAVIR | CABOTEGRAVIR | TENOFOVIR ALAFENAMIDE
Journal Article
Topics in Antiviral Medicine, ISSN 2161-5861, 04/2018, Volume 25, Issue 4, pp. 127 - 132
Over the past 30 years, antiretroviral drug regimens for treating HIV infection have become more effective, safer, and more convenient. Despite 31 currently... 
Fostemsavir | Integrase | Antiretroviral drugs | Cabotegravir | MK-8591 | Antiretroviral therapy | Doravirine | Entry inhibitor | Nonnucleoside | HIV | Bictegravir | Nucleoside | Investigational | Ibalizumab | entry inhibitor | bictegravir | antiretroviral therapy | nucleoside | fostemsavir | doravirine | integrase | nonnucleoside | ibalizumab | investigational | antiretroviral drugs | cabotegravir
Journal Article
Expert Opinion on Investigational Drugs, ISSN 1354-3784, 04/2018, Volume 27, Issue 4, pp. 413 - 420
Introduction: Human Immunodeficiency Virus (HIV) is a chronic infection that depletes the immune system of essential components causing those infected to be at... 
Cabotegravir | HIV-1 treatment | HIV-1 pre-exposure prophylaxis | long-acting | integrase stand transfer inhibitor | AFRICAN WOMEN | SAFETY | ADULTS | ANTIRETROVIRAL THERAPY | DOLUTEGRAVIR | PHASE 2B | ANTIVIRAL ACTIVITY | PHARMACOLOGY & PHARMACY | STRAND TRANSFER INHIBITOR | PREEXPOSURE PROPHYLAXIS | HIV-1 INFECTION
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 07/2019, Volume 306, pp. 89 - 96
Preexposure prophylaxis (PrEP) with antiretrovirals (ARV) can prevent human immunodeficiency virus (HIV) transmission, but its efficacy is highly dependent on... 
Cabotegravir | PrEP | HIV | Implant | Formulation | FUMARATE | GSK1265744 | SAFETY | PREVENTION | DEVICE | ACCEPTABILITY | CHEMISTRY, MULTIDISCIPLINARY | VAGINAL RING | DELIVERY | PHARMACOLOGY & PHARMACY | INFECTION | NANOCHANNELS
Journal Article